Patents by Inventor Paul D. Rennert

Paul D. Rennert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150110792
    Abstract: Antibodies and antibody fragments that bind to human TIM-1 on the BED face of the protein are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit or reduce TIM-1 binding to phosphatidylserine, inhibit or reduce TIM-1 binding to dendritic cells, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: April 23, 2015
    Inventors: Veronique Bailly, Ellen Garber, Paul D. Rennert, Nicholas Joseph Lennemann, Wendy Jean Maury, Sven Henrik Moller-Tank
  • Patent number: 8287874
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: October 16, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • Publication number: 20120156214
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Application
    Filed: June 10, 2010
    Publication date: June 21, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jeffrey L. BROWNING, Paula S. HOCHMAN, Paul D. RENNERT, Fabienne MACKAY
  • Patent number: 7744891
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: June 29, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • Publication number: 20100080798
    Abstract: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-? by lymphocytes or other immune cells in a mammal. Inhibition of IFN-? is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
    Type: Application
    Filed: August 26, 2009
    Publication date: April 1, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Paul D. Rennert
  • Patent number: 7597887
    Abstract: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-? by lymphocytes or other immune cells in a mammal. Inhibition of IFN-? is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: October 6, 2009
    Assignee: Biogen Idec MA Inc.
    Inventor: Paul D. Rennert
  • Publication number: 20090155836
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 18, 2009
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, GENETICS INSTITUTE, LLC, The United States of America as Represented by the Secretary of the Navy
    Inventors: Carl H. JUNE, Craig B. THOMPSON, Gary J. NABEL, Gary S. GRAY, Paul D. RENNERT
  • Patent number: 7479269
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: January 20, 2009
    Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Publication number: 20080219967
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 11, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne MacKay
  • Patent number: 7309492
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: December 18, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne MacKay
  • Patent number: 7255854
    Abstract: Compositions and methods comprising “lymphotoxin-? receptor blocking agents” which block lymphotoxin-? receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: August 14, 2007
    Assignee: Biogen, Inc.
    Inventors: Jeffrey L. Browning, Paula S. Hochman, Paul D. Rennert, Fabienne Mackay
  • Patent number: 7232566
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: June 19, 2007
    Assignees: The United States as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLC
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 7175843
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: February 13, 2007
    Assignees: Genetics Institute, LLC, Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 7144575
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: December 5, 2006
    Assignees: The Regents of the University of Michigan, Genetics Institute, LLC, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 6905681
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: June 14, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 6905680
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: January 26, 1996
    Date of Patent: June 14, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Patent number: 6887466
    Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: May 3, 2005
    Assignees: Genetics Institute, Inc., Regents of the University of Michigan, The United States of America as represented by the Secretary of the Navy
    Inventors: Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
  • Publication number: 20040202650
    Abstract: Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed.
    Type: Application
    Filed: December 9, 2003
    Publication date: October 14, 2004
    Inventors: John G. Gribben, Gordon J. Freeman, Lee M. Nadler, Paul D. Rennert, Cindy L. Jellis, Edward Greenfield, Gary S. Gray
  • Publication number: 20040151725
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Application
    Filed: March 2, 2004
    Publication date: August 5, 2004
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver
  • Patent number: 6750334
    Abstract: CTLA4-immunoglobulin fusion proteins having modified immunoglobulin constant region-mediated effector functions, and nucleic acids encoding the fusion proteins, are described. The CTLA4-immunoglobulin fusion proteins comprise two components: a first peptide having a CTLA4 activity and a second peptide comprising an immunoglobulin constant region which is modified to reduce at least one constant region-mediated biological effector function relative to a CTLA4-IgG1 fusion protein. The nucleic acids of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins in a variety of hosts, particularly eukaryotic cells. The CTLA4-immunoglobulin fusion proteins described herein can be administered to a subject to inhibit an interaction between a CTLA4 ligand (e.g., B7-1 and/or B7-2) on an antigen presenting cell and a receptor for the CTLA4 ligand (e.g.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: June 15, 2004
    Assignee: Repligen Corporation
    Inventors: Gary S. Gray, Jerry Carson, Kashi Javaherian, Cindy L. Jellis, Paul D. Rennert, Sandra Silver